Recruiting
Phase 2

RiMO-301, Pembrolizumab

Sponsor:

University of Illinois Chicago

Code:

NCT07732634

Conditions

Head and Neck Cancer

Head Cancer

Neck Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RiMO-301

Pembrolizumab

Radiation

Surgical resection

Study Details

Brief summary:

The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab). The secondary objectives include determining event-free survival for up to 12 months and overall survival for up to 24 months.

Conditions

Head and Neck Cancer

Head Cancer

Neck Cancer

Study ID

NCT07732634

Start date

Nov 9, 2026

Status verified date

Nov, 2026

Completion date

Nov, 2031

Anticipated

Primary completion date

Nov, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of head and neck cancer that requires surgical resection
  • Must have at least one lesion that is clinically accessible to RiMO-301 injection and amenable to receiving hypofractionated radiotherapy
  • The selected target lesions must be measurable on cross-sectional imaging, and repeated measurements at the same location should be achievable
  • Target tumor not in the previously irradiated field or in the field irradiated at least six months prior to RiMO-301 injection, and with no complications from the prior radiation course
  • Patients must have recovered from acute toxic effects (≤ grade 1 CTCAEv6) of previous cancer treatments prior to enrollment
  • Patients with locally advanced, resectable head and neck cancer:

  • suitable to receive a PD-1 inhibitor (pembrolizumab) as a standard of care in the discretion of the treating physician or Principal Investigator
  • suitable to receive hypofractionated radiotherapy as a standard of care in the discretion of the treating physician or Principal Investigator
  • Have adequate bone marrow reserve:

  • Absolute neutrophil count ≥1.5x10\^9 cell/L
  • Platelet count ≥100x10\^9 cell/L
  • Hemoglobin at least ≥9.0 g/dL unless confirmed by treating physician as not posing any increased harm to patient and approved by Sponsor (transfusion is allowed to achieve hemoglobin of ≥9.0 g/dL 14-days prior to dosing)
  • Have adequate liver function:

  • Total serum bilirubin no more than 1.5x upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5x ULN or ≤5.0x ULN in case of documented hepatic metastasis
  • Alkaline phosphatase ≤5x ULN
  • Have a life expectancy of at least 12 weeks (in the opinion of the investigator)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Females with childbearing potential should be using adequate contraceptive measures from the time of screening until 6 months after study discontinuation, should not be breastfeeding, and must have a negative pregnancy test prior to start of dosing
  • Patients must sign a study-specific informed consent form prior to study entry.

Exclusion Criteria:

\* Diagnosis other than resectable, locally advanced head and neck cancers

  • HPV associated head and neck cancer
  • Nasopharynx head and neck cancer
  • Have signs or symptoms of end-stage failure, major chronic illnesses other than cancer, or any severe concomitant conditions
  • Symptomatic central nervous system metastases and/or carcinomatous meningitis
  • Has received any approved or investigational anti-neoplastic agent or immunotherapy other than PD-1 inhibitors, pembrolizumab, within 4 weeks prior to RiMO-301 injection.
  • Patients who are intolerant to pembrolizumab
  • Active autoimmune disease that has required systemic treatment in the past 2 years
  • Ongoing clinically significant infection at or near the incident lesion
  • Major surgery over the target area (excluding placement of vascular access) ≤21 days from the beginning of the study drug or minor surgical procedures ≤7 days. No waiting is required following implantable port, enteral feeding tube, and catheter placement
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial
  • Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns
  • Patients with a target lesion in the field that had complications from prior radiotherapy that are not amenable to repeat irradiation in the discretion of the treating physician or Principal Investigator
  • Patients with lesions that have significant blood vessel involvement (such as carotid artery encasement) or other major structures

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: RiMO-301 combined with radiotherapy and pembrolizumab followed by surgical resection

RiMO-301 will be injected intratumorally once prior to radiotherapy. Radiotherapy will start within 1 day after the RiMO-301 injection for 5 fractions of 4-5 Grays per fraction over a period of 5-15 days. Pembrolizumab 200 mg will be administered intravenously every 3 weeks (Q3W) within the first dose given on the same day as the RiMO-301 injection (+/-1 day). Pembrolizumab will continue for 2 cycles (1 cycle = 21 days). Surgical resection of the tumor will occur after the completion of neoadjuvant therapy.

Interventions

RiMO-301

RiMO-301 will be dosed on Day 0 prior to radiotherapy. The injection point will be as closed to half of the tumor depth as possible.

Pembrolizumab

Pembrolizumab will be administered at 200 mg once every 3 weeks (Q3W) with the first dose on Day 0 +/- 1 day. Pembrolizumab will be given for a total of two cycles prior to surgery.

Radiation

Hypofractionated radiation will will be given within 1 day after RiMO-301 injection and will continue over a period of 5-15 days. Participants will be receive 5 fractions of radiation with a dose of 4-5 Gray per fraction.

Surgical resection

Surgical resection of the tumor will occur following neoadjuvant therapy.

Primary outcome measure

  • Efficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by major pathologic response (i.e., percentage of participants whose tumors shrink). [ Time Frame: At surgical resection ]

Central Contacts and Locations

Central contacts

Ameen Salahudeen, MD, PhD

(312) 355-1625ameen@uic.edu

Locations

University of Illinois at Chicago

Recruiting

Chicago, Illinois, United States, 60612

Contacts

Ameen Salahudeen, MD, PhD

(312) 355-1625ameen@uic.edu

Principal Investigator:

Ameen Salahudeen, MD, PhD

More Information

Sponsor

University of Illinois Chicago

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by University of Illinois Chicago on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.